Global Liver Institute
News
GLOBAL LIVER INSTITUTE
Congress begins Fiscal Year 2025 appropriations process and the Administration approves new treatments improving the lives of liver disease patients.
After a brief weekend shutdown, Congress passed the FY 2024 appropriations bills and President Joe Biden signed the $1.2 trillion government funding package on March 23, 2024, closing the books on fiscal year (FY) 2024 appropriations.
Celebrating the benefits of drug repurposing for pediatric rare liver disease patients – Pediatric & Rare Liver Diseases News
Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s Livmarli (maralixibat chloride) to address cholestatic pruritus in patients aged 5 and above with progressive familial intrahepatic cholestasis (PFIC).
GLI Celebrates US Treatment for NASH as Milestone for Liver Health – NASH News
The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST NASH therapeutic option in the U.S.
This breakthrough follows years of NASH patient-led multi-stakeholder advocacy and partnership with researchers in drug development.
NIH Launches Research Network To Evaluate Emerging Cancer Screening Technologies – Liver Cancer News
This landmark announcement from the White House follows ongoing advocacy efforts, including a letter to President Joe Biden sent by Prevent Cancer Foundation, GLI, and 80 other advocacy groups to establish Cancer Prevention and Early Detection Month.
Healthy Eating, Healthy Liver: The Links Between Nutrition and Liver Wellness
Maintaining optimal liver health is crucial, given the liver’s pivotal role as a major detoxifying organ. The liver, being a primary filter of toxins and chemicals that pass through the body, is influenced by an individual’s dietary choices.
7th Annual Global Fatty Liver Day is less than 3 months away!
Fatty liver disease is a widespread issue that often goes undetected until it’s too late. It impacts millions worldwide leading to missed opportunities for early intervention and prevention. Studies highlight a concerning gap in identifying patients within the healthcare system who may have fatty liver disease unknowingly. We cannot afford to overlook the silent nature of this and this is why we are advocating for immediate action.
GLI Commends Repurposed Livmarli’s FDA Approval for Patients over 5 with PFIC
(Washington, D.C. March 14, 2024) –Global Liver Institute (GLI) celebrates a win for rare disease patients with the breaking news of the U.S. FDA’s approval for Mirum Pharmaceuticals’ Livmarli to treat cholestasis pruritus in patients 5 and older that have been diagnosed with progressive familial intrahepatic cholestasis (PFIC), a rare, genetic disorder in which bile builds up in the liver.
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication for nonalcoholic steatosis (NASH). Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.
What’s next in line for fatty liver disease? – NASH News
Madrigal Pharmaceuticals celebrates EMA’s validation of the Marketing Authorization Application for Resmetirom, a potential breakthrough therapy for NASH/MASH with liver fibrosis, while eagerly awaiting FDA’s decision, marking significant progress in the fight against liver-related mortality in Europe.
Congress looking to wrap up FY2024 spending bills as they look ahead to FY 2025 appropriations – Liver Health Policy Update
Congress continues to narrowly avert a government shutdown, most recently with yet another Continuing Resolution to extend government funding through later in March.
Navigating Liver Cancer Care – Liver Cancers News
Please join us on April 18 for a liver cancer care webinar open to patients, caregivers, and health care professionals. Experts will discuss topics relevant to the care and treatment of liver cancer and its symptoms so that patients and providers alike can make informed care decisions.
Rare Advocacy on Capitol Hill, in the White House, & Beyond! – Pediatric & Rare Liver Diseases News
In February, GLI raised awareness and amplified the patient voice in discussions about transitions in care for rare liver diseases. Here are a few highlights.